18:57 , Sep 21, 2018 |  BC Week In Review  |  Company News

American Thoracic Society releases updated guidelines for IPF diagnosis

The American Thoracic Society and other international respiratory societies released updated guidelines on Aug. 31 for the diagnosis of idiopathic pulmonary fibrosis (IPF), an indication for which there are only two approved therapies. The guidelines update...
01:21 , Sep 21, 2018 |  BC Innovations  |  Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
23:07 , Sep 19, 2018 |  BC Extra  |  Company News

Management tracks: GSK adds Corsico, Enzmann to chair CHMP

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) hired Chris Corsico, CMO of Boehringer Ingelheim GmbH (Ingelheim, Germany), to lead all development activities for the pharma. As SVP development, Corsico will be based at GSK’s R&D hub in Stevenage,...
17:27 , Sep 14, 2018 |  BC Week In Review  |  Company News

Boehringer to acquire oncolytic virus company ViraTherapeutics

Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised an option to acquire oncolytic virus company ViraTherapeutics GmbH (Innsbruck, Austria). Boehringer gained the option under a 2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its...
21:31 , Sep 13, 2018 |  BC Extra  |  Company News

Boehringer adds to immuno-oncology pipeline with ViraTherapeutics acquisition

Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised an option to acquire oncolytic virus company ViraTherapeutics GmbH (Innsbruck, Austria). Boehringer gained the option under a 2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its...
23:21 , Sep 10, 2018 |  BC Extra  |  Company News

Management tracks: PolarityTE, Medivir

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:COOL) terminated Chief Investment Officer and EVP John Stetson on Friday after the Securities and Exchanges Commission filed charges against him alleging his involvement in "pump-and-dump" schemes (see "Opko's Frost...
18:27 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Exosome play Evox aims for clinic with £35.5M series B

Evox Therapeutics Ltd. (Oxford, U.K.) raised on Sept. 3 £35.5 million ($45.9 million) in a series B round led by Redmile Group. Also participating were GV, Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis Ventures, Oxford...
18:08 , Sep 7, 2018 |  BC Week In Review  |  Company News

Boehringer partners with Chinese university for infectious disease therapies

Boehringer Ingelheim GmbH (Ingelheim, Germany) and Tsinghua University (Beijing, China) partnered to research and develop therapies for infectious diseases using immune modulation. The Tsinghua deal is part of Boehringer's Research Beyond Borders (RBB) program, designed to...
23:30 , Sep 6, 2018 |  BioCentury  |  Finance

Evox populates its pipeline

As Evox Therapeutics Ltd. continues to refine the platform with which it develops exosome-based therapeutics, the company plans to use its £35.5 million ($45.9 million) series B round to start clinical trials on as many...
00:45 , Sep 4, 2018 |  BC Extra  |  Financial News

Exosome play Evox aims for clinic with £35.5M series B

Evox Therapeutics Ltd. (Oxford, U.K.) raised £35.5 million ($45.9 million) in a series B round led by Redmile Group. Also participating were GV, Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis Ventures, Oxford Sciences Innovation (OSI),...